NEW YORK, May 24, 2023 (GLOBE NEWSWIRE) -- H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation (MJFF), has selected its Trial Landscape solution to improve and transform its education and research initiatives.
With nearly one million people in the United States and over six million people worldwide affected by Parkinson's disease (PD), research is crucial in unraveling the mysteries of this condition. Every six minutes, a person in the U.S. is diagnosed with PD. It is imperative to reach out to those living with the disease and provide them with opportunities to participate in research and stay informed about advancements in treatment. By actively participating in studies, individuals with PD can play a vital role in helping scientists uncover the causes of the disease, develop groundbreaking therapies, and find a cure.
A first step in this process is identifying the physicians who are treating PD and gaining a deep understanding of their patient populations. This knowledge will allow for research and clinical trial teams to partner with a more representative population, paving the way for more impactful outcomes in PD research. By partnering with these providers, MJFF aims to educate patients on available studies and encourage participation.
“Engaging diverse populations in clinical studies is critical to advancing treatment and care for all those living with PD,” said Maggie Kuhl, MJFF Vice President of Research Engagement. “We know that many study volunteers learn of these opportunities from their treating physician. More information on who is treating people with PD – and especially populations traditionally underrepresented in research – can help us deliver the information and tools that will enable those conversations and lead to greater representation in studies. H1 Trial Landscape is a valuable tool to identify and connect with those providers.”
With H1’s platform representing more than 10 million healthcare providers globally and over 420,000 clinical trials, MJFF can support its mission of increasing knowledge about the lived experience of Parkinson's disease, engaging patients in research and trials, and supporting the development of new treatments and a cure.
The Michael J. Fox Foundation will use Trial Landscape to streamline its search for physicians who are actively treating Parkinson's disease and gather comprehensive information on their patient populations and treatment approaches. This data will be invaluable in identifying potential contacts for marketing efforts, allowing the Foundation to effectively reach out to physicians who are most likely to be interested in their initiatives. Additionally, Trial Landscape will help the Foundation gain insights into underrepresented patient populations to better understand the specific needs and challenges faced by these groups and develop targeted strategies to support them effectively.
“We are proud to partner with The Michael J. Fox Foundation in their mission of helping the world better understand Parkinson’s and support patients living with the disease,” said Ariel Katz, CEO and co-founder, H1. “As a result of our partnership, the Foundation will have access to our extensive global database of healthcare providers and clinical trials to improve how they connect with physicians and patients, and ultimately make strides in one day finding a cure.”
For more information on Parkinson’s disease or to support The Michael J. Fox Foundation, visit here. For more information on H1 Trial Landscape, visit here.
About H1
H1 connects the world to the right doctors. As the leading source of truth for global healthcare professionals, clinical and scientific information and analytics, H1 leverages next-gen analytics and AI to democratize access to HCP data, diversity insights, and groundbreaking research for life sciences, academic medical institutions, health systems, and payors.
The H1 data platform fuels a robust enterprise product suite that supports the advancement of healthcare innovation and equity. Today, more than 250 customers trust H1 to stay current with the latest information on HCPs everywhere, from clinical work and scholarly research to digital spheres of influence. H1 enables the meaningful connection with thought and treatment leaders to improve adherence to evidence-based medicine, inform inclusive clinical trial design, provide access to groundbreaking science, accelerate time to market, and ultimately, advance health equity.
Learn more at https://www.h1.co.
Media Contact:
Anya Nelson
Scratch Marketing + Media for H1
anyan@scratchmm.com
